A Phase 2,PlaceboControlled,Randomized,Double-Blind,Parallel-Arm Study to EvaluateEfficacy and Safety of BMS-986141For the Prevention of Recurrent Brain Infarction in Subjects receiving acetylsalicyclic acid(ASA)followingAcute Ischemic Stroke or TIA
Clinical Trial Grant
Administered By
Neurology, Neurocritical Care
Awarded By
Bristol-Myers Squibb Company
Start Date
April 1, 2016
End Date
October 31, 2017
Administered By
Neurology, Neurocritical Care
Awarded By
Bristol-Myers Squibb Company
Start Date
April 1, 2016
End Date
October 31, 2017